戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  serve as a generalized lipid-mediated toxin sequestrant.
2 hibited by pertussis toxin, and a Gbetagamma sequestrant.
3 rboxyl terminus of GRK2, a known G betagamma sequestrant.
4 r antagonist, or cholestyramine, a bile acid sequestrant.
5 ts with pruritus not responding to bile salt sequestrants.
6 ted by heterologous expression of Gbetagamma sequestrants.
7  pillararenes) have been investigated as OMP sequestrants.
8                Data from 5 diet, 3 bile acid sequestrant, 1 surgery, and 10 statin trials, with 81,85
9 2/3 inhibition by expression of a Gbetagamma sequestrant, a GRK2/3 dominant-negative mutant, or siRNA
10    Furthermore, expression of the Gbetagamma sequestrant, alpha-transducin, inhibits both Ras activat
11 hat it may show efficacy as an in vivo venom sequestrant and may serve as a generalized lipid-mediate
12 cludes peripheral opioid agonists, bile acid sequestrants and antibiotics, while IBS with constipatio
13        Dose-response relations for bile acid sequestrants and statins are nonlinear, and most of thei
14 d proteins, a PEG-aptamer and oral polymeric sequestrants), and the first follow-on (generic products
15 owering therapy (niacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare benefici
16 dose-response relation of statins, bile acid sequestrants, and niacin and their additive LDL choleste
17 als for the single trials of diet, bile acid sequestrants, and surgery also included the 1:1 relation
18 th added niacin, ezetimibe, and/or bile acid sequestrants, and to understand the implications of thes
19  main therapeutic uses of polymeric drugs as sequestrants, antimicrobials, antivirals, and anticancer
20                         Niacin and bile acid sequestrants appear to exert beneficial effects on ather
21                        Statins and bile-acid sequestrants are effective LDL-lowering therapies for ma
22                                    Bile acid sequestrants are orally administered polymers that bind
23                                    Bile acid sequestrants are synthetic polymers that bind bile acids
24 or synthetic, nonbiological polymer hydrogel sequestrants as a new intervention strategy for sepsis t
25  efficacy and safety of IW-3718, a bile acid sequestrant, as an adjunct to PPI therapy.
26                                           BA sequestrants (BAS) complex bile acids in the intestinal
27                                    Bile acid sequestrants (BAS) lower plasma low density lipoprotein
28                                    Bile acid sequestrants (BAS) reduce LDL-C, yet their clinical effi
29 p 2, we tested whether exposure to bile acid sequestrants (BAS) was associated with risk of dementia.
30 is toxin, decreased by PP1 and the betagamma-sequestrant, but unaffected by PD 98059.
31                                 Developing a sequestrant capable of broad-spectrum neutralization acr
32 atment reversed the effects of the bile acid sequestrant cholestyramine on Fgf15, Shp, and Cyp7a1 exp
33     We repurposed the FDA-approved bile acid sequestrant cholestyramine, which we show binds the anti
34             Supplementation with a bile acid sequestrant, cholestyramine, prevented WD-induced skin i
35 rug Administration approval of the bile acid sequestrant colesevelam HCl for reducing glycemia in pat
36 patients with cholestasis with the bile salt sequestrant, colesevelam, but not placebo, effectively r
37 ministration of a TRPA1 antagonist or the BA sequestrant colestipol, which lowered circulating levels
38          Low-intensity statin plus bile acid sequestrant decreased LDL cholesterol level 0% to 14% mo
39      Here, we report how polymeric 'bacteria sequestrants', designed to bind to bacteria through elec
40 e use increased from 4.2% to 5.0%, bile acid sequestrants did not change significantly, and niacin us
41 cucurbit[n]uril (CB[n]) hosts as solid state sequestrants for a panel of five OMPs.
42  retraining for rectal evacuation disorders, sequestrants for bile acid diarrhea, and secretory agent
43 es of nine sequence-controlled copolymers as sequestrants for rare earth elements (REEs) by incorpora
44 t, high-fat, or high-fat diet with bile acid sequestrant from 6 to 12 months of age.
45        Heterologous expression of Gbetagamma sequestrants (GRK2CT-GFP or Galpha(i)G203A), as well as
46 LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe) (between-grou
47 ble to favor the use of niacin and bile acid sequestrants in combination with statins, based on safet
48  analysed the clinical response of bile acid sequestrants in those patients with a bile acid diarrhoe
49                                    Bile acid sequestrants interrupt intestinal reabsorption of bile a
50    Moreover, the use of niacin and bile acid sequestrants is supported by clinical outcome results fr
51                    The addition of bile acid sequestrant lowered brain Abeta levels in a sexually dim
52 445) trials, and 1 trial each of a bile acid sequestrant (n = 3,806), diet (n = 458), and ileal bypas
53 acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consi
54 wer-intensity statin combined with bile acid sequestrant or ezetimibe among high-risk patients intole
55                                 If bile acid sequestrants or niacin are added to statin therapy, the
56 olesterol-lowering agent (statins, bile acid sequestrants, or niacin, at two or more doses) or 2) mon
57 entation with NAD(+) precursors or bile acid sequestrant partially restored LPD-associated Paneth cel
58 coexpression of a Gbetagamma subunit complex sequestrant peptide (betaARK1ct) and dominant-negative m
59  Ca2+/calmodulin (CAM) inhibitors or the CAM sequestrant protein calspermin.
60                                    The atRAL sequestrant QEA-B-001-NH2 conferred protection against p
61 fter lipid-lowering treatment (statins, bile sequestrant resins).
62 determined that treatment with the bile acid sequestrant sevelamer reversed the liver injury and prev
63 y modification is causal because a bile acid sequestrant suppresses the beneficial effects of bile di
64 geted therapeutic approach using a bile acid sequestrant to improve both cholesterol and glucose mana
65 inhibited by overexpression of the betagamma-sequestrant, transducin.
66  evaluated the association between bile acid sequestrant use and gastric cancer risk in a large human
67 n-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants onl
68 isk was associated with cumulative bile acid sequestrant use.
69 t clinical trials demonstrate that bile acid sequestrants, which significantly reduce LDL-C, can also